

Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Committee

Summary of Main Points from the Meeting held on Monday 9th March 2015

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the December 2014 meeting were approved and will be circulated.

3. Matters Arising

The Committee noted the matters arising from the previous meeting.

4. Formulary Applications

Full applications

No full applications

Individual funding requests (For noting)

- **Alitretinoin**

Decision: Noted

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with Pityriasis rubra pilaris. The CCG have reviewed the application and refused the IFR.

- **Rituximab**

Decision: Noted

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with rheumatoid arthritis.

- **Infliximab**

Decision: Noted

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with chronic plaque psoriasis.

- **Infliximab**

Decision: Noted

Previously approved by the Pharmacoeconomics Board for the management of a specific patient with refractory lung and ocular sarcoidosis.

Ex-Panel Requests

- **Grazax**

Decision: Rejected

Remain as non-formulary for restricted use (military personnel use only)

- **Posaconazole 100mg tablets**

- **Posaconazole 200mg/5ml suspension**

Decision: Rejected

Remain as non-formulary. Pharmacy to keep minimum stock level.

5. Trust Medicines Policy

- **Additional Private Care Policy**

Decision: Noted

Updates to policy that establishes that where a patient opts to pay for private care, their entitlement to NHS services remains and may not be withdrawn.

- **Antimicrobial Prescribing Policy**

Decision: Noted

Policy that defines the processes to ensure antimicrobial prescribing within Chelsea Westminster Hospital NHS Foundation Trust is safe, effective and appropriate for all patients treated by the Trust

6. Medicines Management

- **NWL CSU Contracting Issues 2015/2016**

Decision: Noted

Correspondence relating to NWL changes to outpatient prescribing arrangements 2015/2016

- **Drug Driving Regulations**

Decision: Noted

Drug Driving and Medicine

- **Non Medical Prescribing Lead**

Decision: Noted

Vacancy for non medical prescribing lead

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

- **Risk of distress and death from inappropriate doses of naloxone in patients on long-term opioid/opiate treatment**

Decision: Noted

Relating report and action plan

- **Risk of death or serious harm from accidental ingestion of potassium permanganate preparations**

Decision: Noted

Relating report and action plan

- **Harm from using Low Molecular Weight Heparins when contraindicated**

Decision: Noted

Relating report and action plan

7. NICE TA Guidance

December 2014

- TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Action: Currently included in formulary. To update formulary to indicate that dabigatran is to be used in line with NICE TA327
- TA328 - Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)
Action: No action required as this TA has been terminated

January 2015

- HST1 - Eculizumab for treating atypical haemolytic uraemic syndrome
Action: Not applicable to C&W
- NHSE B06/P/a: Dolutegravir for treatment of HIV-1 in adults and adolescents
Action: Add to formulary

February 2015

- TA330 Sofosbuvir for treating chronic hepatitis C
Action: Add to formulary
- TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
**Action: Infliximab and adalimumab currently on formulary. To update formulary to indicate that infliximab and adalimumab to be used in line with NICE TA329.
Add golimumab to formulary – awaiting application form**
- TA334 - Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (Enclosure XX)
Action: No action required as this TA has been terminated
- TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Action: Currently included in formulary. To update formulary to indicate that axitinib is to be used in line with NICE TA333
- NHSE/A02/PS/c – Interim Clinical Commissioning Policy Statement: Simeprevir for treating Genotype 1 Chronic Hepatitis C TA331 - Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Action: Add to formulary
- TA332 - Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
Action: Nil – not recommended

8. IVIG Update

Decision: Noted

- **IVIG requests**

There were 12 IVIG issues in December 2014, with 4 new requests:

- Two for ITP (red indication)
- One for Secondary antibody deficiency (blue indication)
- One for Myasthenia Gravis (blue indication)

There were 11 IVIG issues in January 2015, with 4 new requests:

- Two for ITP (red indication)
- Two for Myasthenia Gravis (blue indication)

There were 13 IVIG issues in February 2015, with 6 new requests:

- Four for ITP (red indication)

**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee**

- One for Primary immunodeficiency (blue indication)
- One for Necrotising (PVL-associated) staphylococcal sepsis (blue indication)

9. Items for noting

- **Quarterly Controlled Drug Report Q3 2014/15**

Decision: Noted

Quarterly CD Report 2015/2015 Q3

- **Quarterly Controlled Drug Occurrence Report Q3 2014/15**

Decision: Noted

Quarterly CD Occurrence Report 2014/2015 Q3

- **MHRA Update - December 2014**

Decision: Noted

MHRA update for December 2014

- **MHRA Update – January 2015**

Decision: Noted

MHRA update for January 2015

- **MHRA Update – February 2015**

Decision: Noted

MHRA update for February 2015

10. Meeting minutes for noting

- **HIV Drugs Sub-committee meeting – November 2014**

Decision: Noted

- **Local Chemotherapy Group meeting – November 2014**

Decision: Noted

- **Local Chemotherapy Group meeting – January 2015**

Decision: Noted

- **Antibiotic Steering Group meeting – January 2015**

Decision: Noted

13. Date of next meeting

Monday 13th April 2015: 8.00 - 9.00

Board Room: Lower Ground Floor, Lift Bank B

Closing date for papers: Friday 20th March 2015